

Biopharmaceutical development

Over ten years of experience in biologic medicines

2 commercialized biosir Rituximab and Bevaci:

More than six new biosimilars in development

Our portfolio of biopharmaceuticals targets areas of oncology, hematology, osteoporosis and pediatrics.

In-house R&D competencies



End-to-end expertise and capabilities across development of the cell line, formulation, and manufacturing processes for DS and DP, along with robust design and execution of clinical trials.



Strong internal IP portfolio extending beyond research and development to encompass production IP, which ensures our competitive edge in the marketplace.



Outstanding regulatory capabilities with strong scientific review processes and leadership in submissions. Established track records with regulatory authorities worldwide.

CDMO platform

Agile and flexible manufacturing services

Our CDMO services are **fully integrated and tailored to your needs**: from formulation to fill & finish, small-scale or larger quantities.


Single-use bioreactors

For **efficient change over** and minimizing potential cross contamination



We're experts in biopharmaceuticals

We have a proven **track record in delivery** of high-value, high-profile biological projects, from innovators to biosimilars.




State of the art facilities

Three multi-product plants in two continents

With cutting edge technology and GMP approval from regulatory agencies:

FDA | EMA | TGA (Australia) | PMDA (Japan) ANMAT (Argentina) | COFEPRIS (Mexico) Canada | ANVISA (Brazil)

among others



We are mAbxience

A vertically integrated **biotechnology company** dedicated to the development and manufacture of biologics.

B2B presence in

Network of

Team of

MARKETS

30+
PARTNERS

1000+ PEOPLE

Helping people live better

Our mission is to improve patient access to treatments.



